Hua Medicine IPO Preview: Suffering from the Ascletis Over-Valuation Syndrome
Hua Medicine Ltd (2552 HK) which specialises in developing drugs to treat Type 2 diabetes, is the third pre-profit biotech firm to IPO in Hong Kong...
911 Views
Hua Medicine (华领医药) IPO: Little Upside to Fair Value
Hua Medicine launched the institutional book building today and intends to raise USD 111 to USD 124 million, with an implied market capitalization...
584 Views
Last Week in GER Research: Haidilao, Xiaomi, Ping An, 111, Qutoutiao, Nio and Tesla
Below is a recap of the key IPO and fundamental research produced by the Global Equity Research team. This week we highlight a differentiated...
459 Views
Last Week in GER Research: Tesla, Pinduoduo, Beigene, Koolearn, Pintec, STX and China Tower
Below is a recap of the key research produced by the Global Equity Research team. This week we highlight some detailed math on a potential Tesla...
454 Views
BeiGene (6160 HK): On a Stronger Post-Listing Footing than Ascletis
Hong Kong investors have had their first taste of biotech stocks with the recent listings of Ascletis Pharma Inc (1672 HK) and BeiGene Ltd (6160...
552 Views